

# **Europe Monkeypox Testing Market - Industry Outlook and Forecast 2023-2025**

Market Report | 2023-02-15 | 159 pages | Arizton Advisory & Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Team License \$3995.00
- Enterprisewide \$4995.00

### **Report description:**

The Europe monkeypox testing market was valued at USD 18,330.00 thousand in 2022 and is expected to reach USD 56.10 thousand by 2025.

#### KEY MARKET INSIGHTS

- Syndromic tests for monkeypox detection are expected to witness strong growth because they can distinguish monkeypox from other harmful diseases, allowing for easier treatment. On 25th May 2022, Roche and its subsidiary TIB Molbiol announced that they had developed a unique LightMix Modular Virus kit that simultaneously detects orthopoxvirus and offers information on whether an MPXV is present or not, including all MPXV from both the West African and Central African forms of the virus. - Rapid tests in the Europe monkeypox testing market are also expected to witness strong growth due to their rapid results and increasing consumer preference.

- Demand for MPXV testing kits is expected to decline during the forecast as the cases can be seen declining due to increased surveillance, contact tracing, and increasing vaccination across Europe.

Increasing cases and testing are driving the growth of the Europe monkeypox testing market. The growing development of PCR kits as a standard gold method for monkeypox virus detection is propelling the growth of the market in the country. Also, increasing collaborations among In-Vitro Diagnostic (IVD) companies to develop and launch new monkeypox test kits is driving market growth. Surprisingly, the ease in medical device regulation only specific for monkeypox encouraged the IVD companies to bring new testing kits into the market and commercialize it, with PCR kits being the gold standard method. Confirmation of MPXV infection is based on nucleic acid amplification testing (NAAT), which uses conventional or real-time PCR to detect unique viral DNA sequences and is widely used as a standard method to detect MPXV. Increasing activities among vendors are driving the Europe monkeypox testing market growth, including the following:

- In July 2022, ELITechGroup, a France-based privately held manufacturer and distributor of IVD equipment, strategically partnered with Jiangsu Bioperfectus Technologies for monkeypox virus testing across Europe. - In June 2022, Eurobio Scientific launched a CE-marked monkeypox screening test available for hospital use in France.

-[On 8th June 2022, altona Diagnostics, a medical diagnostic company headquartered in Germany, announced the launch of the RealStar Zoonotic Orthopoxvirus PCR Kit 1.0, a real-time RT-PCR based reagent system for the detection of zoonotic (non-variola) Orthopoxvirus species-specific DNA - including MPVX DNA of the Central and West African strains.

-[]On 27th June 2022, Cepheid collaborated with the UK-based global molecular diagnostics company BioGX and announced a partnership between the two companies to provide a PCR test for MPX that will run on the GeneXpert system.

-[In July, the altona Diagnostics company launched another monkeypox virus detection kit, Flexstar Monkeypox virus PCR Detection Mix 1.5, for research purposes.

- Bioactiva Diagnostica is another Germany-based company that offers PCR kits for monkeypox virus detection.

## SEGMENT ANALYSIS

The growing product launches of lateral flow assay kits are expected to create lucrative opportunities for the Europe monkeypox testing market growth. Lateral flow assay is presently not preferred for monkeypox detection in the region because it may give false positive and negative results and because of its high cost. A number of rapid antibody and antigen test kits has been developed. Nanjing Synthgene Medical Technology, a China-based biomedical company, offers CE-certified rapid antibody and antigen tests at USD 1,253 and USD 438, respectively. In contrast, its MPXV Detection Kit (RT-PCR) costs around USD 144 with 24 tests, which means about USD 6 for each test.

Segmentation By Type -[]PCR -[]Lateral Flow Assay -[]Others

The growing surveillance, contact tracing, and vaccine doses across the region are expected to impede market growth by a greater margin. However, it is unclear how much vaccine administrations have contributed to the slowdown in case numbers, and it is also unclear how long vaccine effects will last. In July 2022, the European Commission approved the MPX preventative vaccine, recommended by the European Medicines Agency (EMA).

Segmentation By End-User -[Laboratories -[Hospitals & Clinics -[Others

Bavarian Nordic, a global leader in smallpox vaccines, has been a long-term supplier of the Imvanex vaccine to the US Government and has already supplied the vaccine in the European Union (EU) to many different, often unnamed, European countries. Bavarian Nordic is focused on developing, manufacturing, and commercializing human vaccines. Imvanex vaccine has been authorized to protect adults from MPX disease in the EU since 22nd July 2022.

Since the time of vaccine approval, the region has been ramping up to supply vaccine doses to every country dealing with the highest number of cases. Vaccine administration and contact tracing have rapidly increased in Spain, the second country after the US, with the highest number of confirmed cases since June 2022. On 20th October 2022, National Health Service (NHS) launched a new online vaccine site finder to make it easy for eligible people to vaccinate.

## **REGIONAL ANALYSIS**

In 2022, EU-5 accounted for the largest share of 77.71% in the Europe monkeypox testing market. In EU-5, Spain accounts for the highest revenue share, followed by France, UK, Germany, and Italy, which can be attributed to increasing cases, and increased testing. More than 98% of cases are identified in men who have sex with men in EU-5. The Netherlands is vaccinating high-risk people against MPX using two doses of the Imvanex smallpox vaccine. Until 3rd August 2022, 1,976 people in the Netherlands

received a preventive vaccination against the MPXV.

In Berlin, Germany, vaccinations against the viral infection had begun in mid-July. In July, The Standing Commission on Vaccination (Stiko) recommended this for certain groups and people who have had close contact with infected persons. It sees an increased risk of infection, particularly among men who have same-sex sexual contact with changing partners. According to the Senate Department for Health, demand for the MPX vaccine is very high in Berlin; however, the vaccine is still in very short supply. The shortage in vaccine supply has increased the chances of spreading MPX, which implicitly increases the possibilities of the Europe monkeypox testing market growth. However, in the future, the growing number of vaccinations for monkeypox may hinder the growth of the MPX testing market. In addition, as the currently authorized vaccine, Imvanex is not authorized for children and pregnant women, the growth of MPX testing still holds growth opportunities during the forecast period. Also, an increase in risky behavior may cause a resurgence of the virus that may keep the opportunity for MPX testing market demand.

Segmentation By Region -[Europe o]EU-5 -[Spain -[France -[UK -[Germany -[Italy o]Central, Eastern, and Southern Europe -[Netherlands -[Portugal -[Switzerland o[Nordic -[Sweden -[Denmark

VENDOR LANDSCAPE

- Hoffmann-La Roche - Qiagen -naltona Diagnostics - Autobio Applied DNA Sciences Aurora Biomed - bioactiva diagnostica - Beijing Hotgen Biotech -[]BioGX - CERTEST BIOTEC - Creative Biogene -∏CorDx - CLONIT - Eurobio Scientific -∏FireGene -∏GenScript - Guangzhou Pluslife Biotech - OYSBIO (Tianjin) Biotechnology

- Nanjing Synthgene Medical Technology

-[RayBiotech Life -[Sansure Biotech -[Virax Biolabs -[Wondfo -[Shanghai Biogerm Medical Technology KEY QUESTIONS ANSWERED

How big is the Europe monkeypox testing market? What is the projected growth rate of the Europe monkeypox testing market during the forecast period? What are the growing trends in the Europe monkeypox testing market? Which region holds the largest Europe monkeypox testing market share? Which are the key players in the Europe monkeypox testing market?

## Table of Contents:

1 RESEARCH METHODOLOGY
 2 RESEARCH OBJECTIVES
 3 RESEARCH PROCESS

4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY TYPE
4.3.2 MARKET SEGMENTATION BY END-USER
4.3.3 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS 5.1 KEY CAVEATS 5.2 CURRENCY CONVERSION 5.3 MARKET DERIVATION

6 PREMIUM INSIGHTS 6.1 OVERVIEW

7 MARKET AT A GLANCE 8 INTRODUCTION 8.1 OVERVIEW

9 MARKET OPPORTUNITIES & TRENDS9.1 DEVELOPMENT OF RAPID TESTING METHODS9.2 ADVANCES IN PCR TECHNOLOGY9.3 VENDOR COLLABORATIONS

**10 MARKET GROWTH ENABLERS** 

10.1 INCREASED GOVERNMENT SURVEILLANCE10.2 EASE OF REGULATIONS FOR PRODUCT APPROVALS10.3 INCREASED PRODUCT LAUNCHES

11 MARKET RESTRAINTS 11.1 DECLINE IN MPX CASES 11.2 MPX VACCINE APPROVAL & ACCESS 11.3 FALSE MPX TEST RESULTS

12 MARKET LANDSCAPE 12.1 MARKET OVERVIEW 12.1.1 INSIGHTS BY TYPE 12.1.2 INSIGHTS BY END-USER 12.1.3 INSIGHTS BY GEOGRAPHY 12.2 FIVE FORCES ANALYSIS 12.2.1 THREAT OF NEW ENTRANTS 12.2.2 BARGAINING POWER OF SUPPLIERS 12.2.3 BARGAINING POWER OF BUYERS 12.2.4 THREAT OF SUBSTITUTES 12.2.5 COMPETITIVE RIVALRY

13 TEST TYPE

13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 PCR
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.4 LATERAL FLOW ASSAYS
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.5 OTHERS
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST

14 END-USER
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 LABORATORIES
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.4 HOSPITALS & CLINICS
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.5 OTHERS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST

15 GEOGRAPHY 15.1 MARKET SNAPSHOT & GROWTH ENGINE 15.2 MARKET OVERVIEW

16 EU-5 16.1 MARKET OVERVIEW 16.2 MARKET SIZE & FORECAST 16.3 KEY COUNTRIES 16.3.1 SPAIN: MARKET SIZE & FORECAST 16.3.2 FRANCE: MARKET SIZE & FORECAST 16.3.3 UK: MARKET SIZE & FORECAST 16.3.4 GERMANY: MARKET SIZE & FORECAST 16.3.5 ITALY: MARKET SIZE & FORECAST

17 CENTRAL, EASTERN & SOUTHERN EUROPE
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.3 KEY COUNTRIES
17.3.1 NETHERLANDS: MARKET SIZE & FORECAST
17.3.2 PORTUGAL: MARKET SIZE & FORECAST
17.3.3 SWITZERLAND: MARKET SIZE & FORECAST

18 NORDICS
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.3 KEY COUNTRIES
18.3.1 SWEDEN: MARKET SIZE & FORECAST
18.3.2 DENMARK: MARKET SIZE & FORECAST

19 COMPETITIVE LANDSCAPE 19.1 COMPETITION OVERVIEW 19.2 MARKET SHARE ANALYSIS 19.2.1 F. HOFFMANN-LA ROCHE 19.2.2 QIAGEN

20 KEY COMPANY PROFILES 20.1 F. HOFFMANN-LA ROCHE 20.1.1 BUSINESS OVERVIEW 20.1.2 PRODUCT OFFERINGS 20.1.3 KEY STRATEGIES 20.1.4 KEY STRENGTHS 20.1.5 KEY OPPORTUNITIES 20.2 QIAGEN 20.2.1 BUSINESS OVERVIEW 20.2.2 PRODUCT OFFERINGS 20.2.3 KEY STRATEGIES 20.2.4 KEY STRENGTHS

21 OTHER PROMINENT VENDORS **21.1 ALTONA DIAGNOSTICS** 21.1.1 BUSINESS OVERVIEW 21.1.2 PRODUCT OFFERINGS 21.2 AUTOBIO 21.2.1 BUSINESS OVERVIEW 21.2.2 PRODUCT OFFERINGS 21.3 APPLIED DNA SCIENCES 21.3.1 BUSINESS OVERVIEW 21.3.2 PRODUCT OFFERINGS 21.4 AURORA BIOMED 21.4.1 BUSINESS OVERVIEW 21.4.2 PRODUCT OFFERINGS 21.5 BIOACTIVA DIAGNOSTICA 21.5.1 BUSINESS OVERVIEW 21.5.2 PRODUCT OFFERINGS 21.6 BEIJING HOTGEN BIOTECH 21.6.1 BUSINESS OVERVIEW 21.6.2 PRODUCT OFFERINGS **21.7 BIOGX** 21.7.1 BUSINESS OVERVIEW 21.7.2 PRODUCT OFFERINGS **21.8 CERTEST BIOTEC** 21.8.1 BUSINESS OVERVIEW 21.8.2 PRODUCT OFFERINGS **21.9 CREATIVE BIOGENE** 21.9.1 BUSINESS OVERVIEW 21.9.2 PRODUCT OFFERINGS 21.10 CORDX 21.10.1 BUSINESS OVERVIEW 21.10.2 PRODUCT OFFERINGS 21.11 CLONIT 21.11.1 BUSINESS OVERVIEW 21.11.2 PRODUCT OFFERINGS 21.12 EUROBIO SCIENTIFIC 21.12.1 BUSINESS OVERVIEW 21.12.2 PRODUCT OFFERINGS 21.13 FIREGENE 21.13.1 BUSINESS OVERVIEW 21.13.2 PRODUCT OFFERINGS 21.14 GENSCRIPT 21.14.1 BUSINESS OVERVIEW 21.14.2 PRODUCT OFFERINGS 21.15 GUANGZHOU PLUSLIFE BIOTECH 21.15.1 BUSINESS OVERVIEW

21.15.2 PRODUCT OFFERINGS 21.16 JOYSBIO (TIANJIN) BIOTECHNOLOGY 21.16.1 BUSINESS OVERVIEW 21.16.2 PRODUCT OFFERINGS 21.17 NANJING SYNTHGENE MEDICAL TECHNOLOGY 21.17.1 BUSINESS OVERVIEW 21.17.2 PRODUCT OFFERINGS 21.18 RAYBIOTECH LIFE 21.18.1 BUSINESS OVERVIEW 21.18.2 PRODUCT OFFERINGS 21.19 SANSURE BIOTECH 21.19.1 BUSINESS OVERVIEW 21.19.2 PRODUCT OFFERINGS 21.20 VIRAX BIOLABS 21.20.1 BUSINESS OVERVIEW 21.20.2 PRODUCT OFFERINGS 21.21 WONDFO 21.21.1 BUSINESS OVERVIEW 21.21.2 PRODUCT OFFERINGS 21.22 SHANGHAI BIOGERM MEDICAL TECHNOLOGY 21.22.1 BUSINESS OVERVIEW 21.22.2 PRODUCT OFFERINGS

22 REPORT SUMMARY 22.1 KEY TAKEAWAYS 22.2 STRATEGIC RECOMMENDATIONS

23 QUANTITATIVE SUMMARY 23.1 MARKET BY GEOGRAPHY 23.2 MARKET BY TYPE 23.3 MARKET BY END-USER

24 APPENDIX 24.1 ABBREVIATIONS



# **Europe Monkeypox Testing Market - Industry Outlook and Forecast 2023-2025**

Market Report | 2023-02-15 | 159 pages | Arizton Advisory & Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

#### **ORDER FORM:**

Select license	License		Price
	Single User License		\$3500.00
	Team License		\$3995.00
	Enterprisewide		\$4995.00
		VAT	
		Total	

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIP number*	
Address*	City*	
Zip Code*	Country*	
	Date	2025-06-25
	Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com